Diabetes.co.uk reports the late-stage result for Lilly's experimental drug in people with type 2 diabetes. Tap through for the trial details.
Recap by typeshit. Post by Diabetes.co.uk on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A study in a South American medical journal suggests a possible benefit tied to GLP-1 drugs. The teaser leaves out what improved, so tap through for specifics.
BusinessWorld Online lists a new FDA warning covering weight loss drugs such as Wegovy. The listing doesn't say what the warning is about, so check the source for details.
Loading…